Patents by Inventor Bradley Tait

Bradley Tait has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteasome activity enhancing compounds
    Patent number: 11958873
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 16, 2024
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20240116894
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: July 12, 2023
    Publication date: April 11, 2024
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • Proteasome activity enhancing compounds
    Patent number: 11746098
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 5, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230242557
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 3, 2023
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20230058189
    Abstract: The present disclosure relates to quinolin-4-one and 4(1H)-cinnolinone compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.
    Type: Application
    Filed: February 7, 2020
    Publication date: February 23, 2023
    Applicant: Frequency Therapeutics, Inc.
    Inventors: Bradley TAIT, Megan S. HARRISON, Will MCLEAN
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20220298181
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 22, 2022
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS
    Publication number: 20220192984
    Abstract: The present disclosure relates to pharmaceutical compositions (e.g., pre-lyophilized pharmaceutical compositions, lyophilized pharmaceutical compositions, and reconstituted solutions) comprising one or more otic therapeutic agents. The present disclosure also relates to methods of preparing the pharmaceutical compositions, and methods of using the pharmaceutical compositions for therapeutic purpose.
    Type: Application
    Filed: October 2, 2019
    Publication date: June 23, 2022
    Inventors: Will MCLEAN, Rajesh MANCHANDA, Snehal KHEDKAR, Richard A. STRONG, Jr., Ashley BANKS, Bradley TAIT, Christopher LOOSE
  • TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS
    Publication number: 20220160664
    Abstract: Provided are compositions and methods comprising a TAZ activator and a Wnt agonist for increasing proliferation of cochlear supporting cells or vestibular supporting cells, and related methods of treating inner ear hearing or balance disorders.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 26, 2022
    Inventors: Will MCLEAN, Megan S. HARRISON, Bradley TAIT
  • COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS
    Publication number: 20220127568
    Abstract: Provided are compositions and methods comprising an epigenetic agent and a Wnt agonist for increasing proliferation of cochlear supporting cells or vestibular supporting cells, and related methods of treating inner ear hearing or balance disorders.
    Type: Application
    Filed: February 7, 2020
    Publication date: April 28, 2022
    Applicant: Frequency Therapeutics, Inc.
    Inventors: Will MCLEAN, Megan HARRISON, Melissa HILL-DRZEWI, Bradley TAIT
  • Proteasome activity enhancing compounds
    Patent number: 11242361
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS
    Publication number: 20210300948
    Abstract: The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 30, 2021
    Inventors: Christopher LOOSE, Bradley TAIT, Rajesh MANCHANDA, Will MCLEAN
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 11098035
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 24, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • 1H-pyrrole-2,5-dione compounds and methods of using same
    Patent number: 11066419
    Abstract: The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 20, 2021
    Assignee: Frequency Therapeutics, Inc.
    Inventors: Christopher Loose, Bradley Tait, Rajesh Manchanda, Will Mclean
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20210188802
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 24, 2021
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20200316089
    Abstract: The present disclosure relates to 1,2-dihydro-3H-pyrazol-3-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Inventors: Christopher LOOSE, Bradley TAIT, Rajesh MANCHANDA, Will MCLEAN
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20200308198
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEOSTASIS REGULATORS
    Publication number: 20200299270
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Application
    Filed: November 21, 2019
    Publication date: September 24, 2020
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10738011
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10738040
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20200190072
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Application
    Filed: July 12, 2019
    Publication date: June 18, 2020
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait